Diabetes disrupts the response of retinal endothelial cells to the angiomodulator lysophosphatidic acid

Diabetes

Volumn 61, Issue 5, 2012, Pages 1225-1233

  Aranda, Jorge ^a   Motiejunaite, Ruta ^a,b   Im, Eunok ^c   Kazlauskas, Andrius ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b VILNIUS UNIVERSITY   (Lithuania)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; GLUCOSE; LYSOPHOSPHATIDIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; ENDOTHELIUM CELL; EXPLANT; HUMAN; HUMAN CELL; HYPERGLYCEMIA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RETINA; STREPTOZOCIN DIABETES;

ANIMALS; CATTLE; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; LYSOPHOSPHOLIPIDS; MAP KINASE KINASE KINASES; PROTO-ONCOGENE PROTEINS PP60(C-SRC); REACTIVE OXYGEN SPECIES; RETINA; RETINAL VESSELS;

EID: 84860555583     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1189     Document Type: Article

References (39)

1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376: 124-136
2. Chew EY, Ambrosius WT, Davis MD, et al.; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-244
3. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487 (Pubitemid 24356306)
4. Manaviat MR, Rashidi M, Afkhami-Ardekani M, Mohiti-Ardekani J, Bandala-Sanchez M. Effect of pan retinal photocoagulation on the serum levels of vascular endothelial growth factor in diabetic patients. Int Ophthalmol 2011;31:271-275
5. Cury CE Jr, Rodrigues EB, Meyer CH, Farah ME. VEGF inhibitors and vitrectomy for diabetic vitreoretinopathy. Dev Ophthalmol 2009;44:69-81
6. Adamis AP, Altaweel M, Bressler NM, et al.; Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-28 (Pubitemid 43021723)
7. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008;18:263-269 (Pubitemid 351692187)
8. Gao BB, Clermont A, Rook S, et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007;13:181-188
9. Tong Z, Yang Z, Patel S, et al.; Genetics of Diabetes and Diabetic Complication Study Group. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci USA 2008;105:6998-7003 (Pubitemid 351754519)
10. Elayappan B, Ravinarayannan H, Pasha SPBS, Lee KJ, Gurunathan S. PEDF inhibits VEGF- and EPO- induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation. Angiogenesis 2009;12:313-324
11. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31
12. Im E, Motiejunaite R, Aranda J, et al. Phospholipase Cgamma activation drives increased production of autotaxin in endothelial cells and lysophosphatidic acid-dependent regression. Mol Cell Biol 2010;30:2401-2410
13. Moolenaar WH, van Meeteren LA, Giepmans BNG. The ins and outs of lysophosphatidic acid signaling. Bioessays 2004;26:870-881 (Pubitemid 39128101)
14. Lee CW, Rivera R, Dubin AE, Chun J. LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. J Biol Chem 2007;282:4310-4317 (Pubitemid 47100980)
15. Noguchi K, Herr D, Mutoh T, Chun J. Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 2009;9:15-23
16. Yanagida K, Masago K, Nakanishi H, et al. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem 2009;284:17731-17741
17. Nam SW, Clair T, Kim YS, et al. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 2001;61:6938-6944 (Pubitemid 32896522)
18. Tanaka M, Okudaira S, Kishi Y, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 2006;281:25822-25830 (Pubitemid 44401970)
19. Bodin S, Chollet C, Goncalves-Mendes N, et al. Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int 2009;76:395-403
20. Im E, Kazlauskas A. Src family kinases promote vessel stability by antagonizing the Rho/ROCK pathway. J Biol Chem 2007;282:29122-29129 (Pubitemid 350043365)
21. Im E, Venkatakrishnan A, Kazlauskas A. Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell 2005;16:3488-3500 (Pubitemid 41077063)
22. Saulnier-Blache JS, Girard A, Simon MF, Lafontan M, Valet P. A simple and highly sensitive radioenzymatic assay for lysophosphatidic acid quantification. J Lipid Res 2000;41:1947-1951 (Pubitemid 32038989)
23. Kume K, Shimizu T. cDNA cloning and expression of murine 1-acyl-snglycerol-3-phosphate acyltransferase. Biochem Biophys Res Commun 1997;237:663-666 (Pubitemid 27434744)
24. Im E, Kazlauskas A. Regulating angiogenesis at the level of PtdIns-4,5-P2. EMBO J 2006;25:2075-2082
25. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820 (Pubitemid 34000785)
26. Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 2008;9:315-327
27. Lin RZ, Wang TP, Hung RJ, Chuang YJ, Chien CC, Chang HY. Tumor-induced endothelial cell apoptosis: roles of NAD(P)H oxidase-derived reactive oxygen species. J Cell Physiol 2011;226:1750-1762
28. Tajima M, Kurashima Y, Sugiyama K, Ogura T, Sakagami H. The redox state of glutathione regulates the hypoxic induction of HIF-1. Eur J Pharmacol 2009;606:45-49
29. Chowdhury AK, Watkins T, Parinandi NL, et al. Src-mediated tyrosine phosphorylation of p47phox in hyperoxia-induced activation of NADPH oxidase and generation of reactive oxygen species in lung endothelial cells. J Biol Chem 2005;280:20700-20711 (Pubitemid 40776775)
30. Abid MR, Spokes KC, Shih SC, Aird WC. NADPH oxidase activity selectively modulates vascular endothelial growth factor signaling pathways. J Biol Chem 2007;282:35373-35385 (Pubitemid 350232487)
31. Mavria G, Vercoulen Y, Yeo M, et al. ERK-MAPK signaling opposes Rhokinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 2006;9:33-44 (Pubitemid 43069509)
32. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 2009;15:1298-1306
33. Yeh PT, Yang CM, Huang JS, Chien CT, Yang CH, Chiang YH, et al. Vitreous levels of reactive oxygen species in proliferative diabetic retinopathy. Ophthalmology 2008;115:734-737
34. Garcia-Medina JJ, Pinazo-Duran MD, Garcia-Medina M, Zanon-Moreno V, Pons-Vazquez S. A 5-year follow-up of antioxidant supplementation in type 2 diabetic retinopathy. Eur J Ophthalmol 2011;21:637-643
35. Millen AE, Klein R, Folsom AR, Stevens J, Palta M, Mares JA. Relation between intake of vitamins C and E and risk of diabetic retinopathy in the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 2004;79:865-873 (Pubitemid 41103889)
36. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008;456:809-813
37. Huang D, Ding Y, Li Y, et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010;70:1053-1062
38. Zhong H, Wang D, Wang N, et al. Combinatory action of VEGFR2 and MAP kinase pathways maintains endothelial-cell integrity. Cell Res 2011;21: 1080-1087
39. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270